Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β

Volume: 208, Issue: 1, Pages: 169 - 180
Published: Jan 1, 2022
Abstract
Adoptive T cell therapy with T cells expressing affinity-enhanced TCRs has shown promising results in phase 1/2 clinical trials for solid and hematological tumors. However, depth and durability of responses to adoptive T cell therapy can suffer from an inhibitory tumor microenvironment. A common immune-suppressive agent is TGF-β, which is secreted by tumor cells and cells recruited to the tumor. We investigated whether human T cells could be...
Paper Details
Title
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β
Published Date
Jan 1, 2022
Volume
208
Issue
1
Pages
169 - 180
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.